Integrating Immune and Nutritional Biomarkers to Predict Platinum Resistance and Clinical Outcomes in Epithelial Ovarian Cancer: A Multi-Index Analysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202511744488222

Enrollment

Registered

2025-11-26

Start date

2025-11-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

GrIm score

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: o Histologically confirmed epithelial ovarian cancer o Will be treated with NAC platinum-based chemotherapy o Will receive NAC platinum based chemotherapy o ECOG PS =2

Exclusion criteria

Exclusion criteria: o Non-epithelial ovarian tumors o Metastatic cases o Medically inoperable cases o Patients with concurrent infections or autoimmune diseases affecting systemic inflammation o Previous treatment for ovarian cancer (chemotherapy, radiotherapy, or surgery) o Previous treatment with platinum for cancers other than ovarian cancer o Impaired renal function with CrCl<40 ml/min

Design outcomes

Primary

Measure	Time frame
Evaluation of the predictive value of the Gustave Roussy Immune Score (GRIm-score), systemic immune-inflammation index (SII), and prognostic nutritional index (PNI) in identifying platinum resistance and predicting prognosis in epithelial ovarian cancer patients.	—

Secondary

Measure	Time frame
Overall Survival (OS) — time from initial diagnosis (or treatment initiation) to death from any cause	—

Countries

Egypt

Contacts

Public ContactDina Ehab Sayed Kamel

residant doctor at clinical oncology department Assiut university

Dina.17310335@med.aun.edu.eg+201011016197

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026